Tag: auristatin F hydroxypropylamide
Mersana Therapeutics and Janssen Biotech Sign Agreement to Advance Novel Antibody-Drug...
Mersana Therapeutics has signed a research collaboration and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to...
Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...
Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...
Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC...
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC with a high drug-antibody ratio...
Mersana Presents Updated Data about its Dolasynthen Platform and Synthemer Scaffold
Clinical-stage bio-pharmaceutical company, Mersana Therapeutics, presented preclinical data from the company's proprietary Dolasynthen platform and its modular Synthemer scaffold during the 2019 Annual Meeting...